C4 Therapeutics, Inc. announced a clinical trial collaboration and supply agreement with Pfizer Inc. This agreement is a significant step for C4T's lead candidate, cemsidomide, in the treatment of relapsed/refractory multiple myeloma. Under the terms, Pfizer will supply its B-cell maturation antigen CD3 targeted bispecific antibody, elranatamab (ELREXFIO®), to C4T.
The collaboration will support C4T's upcoming Phase 1b trial, which is expected to initiate in Q2 2026. This trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab. The goal is to establish an optimal dose for this triple combination as a second-line or later therapy for multiple myeloma patients.
Pfizer will provide elranatamab at no cost to C4T, while C4T will sponsor and conduct the trial. This arrangement significantly de-risks the development of this combination therapy for C4T. Andrew Hirsch, C4T's CEO, highlighted that this agreement creates an opportunity for cemsidomide to be combined with elranatamab, which is on a path to potentially becoming a standard of care BCMAxCD3 bispecific in a growing market.
Data from cemsidomide's Phase 1 trial in relapsed/refractory multiple myeloma demonstrated robust T-cell activation and cytokine expression across multiple doses. By activating immune T-cells, cemsidomide, when combined with a BCMAxCD3 bispecific like elranatamab, may amplify the anti-myeloma immune response and lead to higher quality of responses, offering a new treatment regimen for patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.